Tyme Technologies Inc (NASDAQ:TYME)’s stock price shot up 8.8% during trading on Monday . The stock traded as high as $1.38 and last traded at $1.36, 948,858 shares were traded during trading. An increase of 34% from the average session volume of 706,384 shares. The stock had previously closed at $1.25.

A number of equities research analysts have recently weighed in on TYME shares. HC Wainwright started coverage on shares of Tyme Technologies in a report on Monday, August 12th. They set a “buy” rating on the stock. Zacks Investment Research upgraded Tyme Technologies from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research note on Friday, August 16th.

The stock has a 50-day moving average of $1.12 and a 200 day moving average of $1.48. The stock has a market cap of $152.25 million, a PE ratio of -4.88 and a beta of 0.37.

Tyme Technologies (NASDAQ:TYME) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. On average, equities analysts predict that Tyme Technologies Inc will post -0.22 EPS for the current fiscal year.

In other news, major shareholder Michael Demurjian sold 50,000 shares of the business’s stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $1.18, for a total value of $59,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Carberry acquired 30,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was bought at an average cost of $1.07 per share, with a total value of $32,100.00. The disclosure for this purchase can be found here. In the last quarter, insiders bought 60,000 shares of company stock worth $63,450 and sold 220,000 shares worth $246,900. 27.17% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Morgan Stanley boosted its position in Tyme Technologies by 187.8% in the 2nd quarter. Morgan Stanley now owns 139,579 shares of the company’s stock worth $170,000 after purchasing an additional 91,081 shares in the last quarter. Paloma Partners Management Co purchased a new stake in Tyme Technologies during the second quarter worth $238,000. Bank of New York Mellon Corp grew its position in Tyme Technologies by 5.9% during the second quarter. Bank of New York Mellon Corp now owns 306,199 shares of the company’s stock valued at $374,000 after buying an additional 17,173 shares during the period. SG Americas Securities LLC purchased a new position in Tyme Technologies in the first quarter valued at $27,000. Finally, BNP Paribas Arbitrage SA purchased a new position in Tyme Technologies in the first quarter valued at $46,000. Institutional investors own 14.96% of the company’s stock.

About Tyme Technologies (NASDAQ:TYME)

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Featured Story: What is a Backdoor Roth IRA?

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.